Seres Therapeutics, Inc. (MCRB)

5.69 +0.02 (+0.35%) At close: 04:00PM EDT

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617 945 9626
https://www.serestherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 333

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eric D. Shaff M.B.A.	Pres, CEO & Director	953.1k	N/A	1976
Mr. David A. Arkowitz M.B.A.	Exec. VP, CFO & Head of Bus. Devel.	603.33k	N/A	1961
Dr. Matthew R. Henn Ph.D.	Exec. VP & Chief Scientific Officer	591.78k	N/A	1975
Dr. David S. Ege Ph.D.	Exec. VP & Chief Technology Officer	N/A	N/A	1974
Mr. Carlo Tanzi Ph.D.	Investor Relations Officer	N/A	N/A	N/A
Mr. Thomas J. DesRosier Esq., J.D.	Chief Legal Officer, Exec. VP & Sec.	N/A	N/A	1955
Ms. Kristin Ainsworth	Sr. VP of Corp. Communications	N/A	N/A	N/A
Ms. Paula A. Cloghessy SHRM-SCP, SPHR	Exec. VP & Chief People Officer	N/A	N/A	1972
Dr. Lisa von Moltke M.D.	Exec. VP & Chief Medical Officer	N/A	N/A	1959
Dr. Teresa L. Young Ph.D., R.Ph.	Exec. VP and Chief Commercial & Strategy Officer	N/A	N/A	1967

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Seres Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.